Top 4 Challenges for Vaccine Manufacturers

Recently we undertook the research for the 15th annual World Vaccine Congress, and so asked what the biggest challenges are for each segment of the market. When we spoke to vaccine manufacturers, these came up as the 4 biggest issues:   1)      Adjuvants Adjuvants are often lauded as the way forward to make vaccines more effective, but given how new …

6 Novel Adjuvants in Development

[imagebrowser=6] If you want to know more about vaccines, and meet innovators, disruptors and influencers from across the vaccine research, development and technology landscape, find out about the World Vaccine Congress Europe 2013, 16-17 October 2013, Lille. Download the brochure >   Read more: Global eradication: 4 terrible diseases being shown the door

Presentation: Vaccine development formulation with adjuvants

In November 2012 over 200 delegates participated in the 13th Annual World Vaccine Congress Lyon in France. This event brings together vaccine leaders and policy makers from around the globe. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Emanuele Montomoli from the Lab. of Molecular Epidemiology, University of Siena entitled: ‘Vaccine development …

Download presentation: Challenges to Using Adjuvants

In November 2012 over 200 delegates participated in the 13th Annual World Vaccine Congress Lyon in France. This event brings together vaccine leaders and policy makers from around the globe.  Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Martin Friede (Team Leader, WHO), ‘Challenges to Using Adjuvants'. This presentation focuses on: Adjuvants …

Enhancing existing vaccines, developing technologies for biodefense vaccines

Biodefense is traditionally a term associated with defensive measures taken against biological attack. Dr Michael Kurilla, Director, Office of BioDefense Research Affairs & Associate Director for BioDefense Product Development, DMID, NIAID, NIH, DHHS, spoke at the World Vaccine Congress 2012 in Washington on the application of biodefense to existing vaccines to prevent the potential impact from future pandemics. The necessity …

FDA & EMA viewpoints: regulating adjuvanted #influenza #vaccines

Dr Pieter Neels, Member Committee for Medicinal Products for Human Use at the European Medicines Agency spoke at last year's World Influenza Congress in Vienna on the reasoning behind regulatory standpoints in Europe.   And he did address the elephant in the room before getting started, saying that:   "Regulators cannot do any good: If we are critical: we are …

2020 vision for vaccines against HIV, tuberculosis and malaria

Rino Rappuoli, PhD, is Global Head of Vaccines Research at Novartis Vaccines and Diagnostics and is based in Siena, Italy.   In one of his most recent publications in Nature together with Alan Aderem, they discuss their 2020 vision for vaccines against HIV, tuberculosis and malaria.   Acquired immune deficiency syndrome (AIDS), malaria and tuberculosis collectively cause more than five …